The hypothesis is that 0.5 g/kg/wk of IvIG is as effective as 1.0 g/kg/wk, in the prevention of ICH in FNAIT.
ID
Bron
Verkorte titel
Aandoening
Fetal or Neonatal Alloimmune Thrombocytopenia
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Number of neonates with intracranial hemorrhage.
Achtergrond van het onderzoek
The major complication of fetal or neonatal alloimmune thrombocytopenia (FNAIT) is intra cranial hemorrhage (ICH) in the child, resulting in severe morbidity or death.
There are both clinical and experimental indications that intravenous immunoglobulines (IvIG) prevents ICH in the fetus and newborn.
Since the first reported study of treating pregnant women with FNAIT with IvIG, the most commonly used dose has been 1 gram per kilogram bodyweight per week (g/kg/wk). I
n one study corticosteroids were added and in another study 2 g/kg/wk has been administered, without apparent benefit (Bussel, 2001; Bussel, 1996).
Given the lack of rationale for the dose of 1 g/kg/wk, the cost of IvIG and the unknown long-term effects of IvIG on the infants, we plan to compare a lower dose with the standard dose IvIG.
The aim of this study is to compare the preventive effect of 0.5 with 1.0 g/kg/week IvIG on FNAIT and ICH, using an international multi-center, randomized controlled trial in patients with FNAIT and a low risk for ICH.
Doel van het onderzoek
The hypothesis is that 0.5 g/kg/wk of IvIG is as effective as 1.0 g/kg/wk, in the prevention of ICH in FNAIT.
Onderzoeksproduct en/of interventie
Study group: low dose IvIG (0.5 g/kg/wk);
Control group, standard treatment: high dose IvIG (1.0 g/kg/wk).
Publiek
Department of Obstetrics, K6-31,
P.O. Box 9600
D. Oepkes
Leiden 2300 RC
The Netherlands
+31 (0)71 5263360
D.Oepkes@lumc.nl
Wetenschappelijk
Department of Obstetrics, K6-31,
P.O. Box 9600
D. Oepkes
Leiden 2300 RC
The Netherlands
+31 (0)71 5263360
D.Oepkes@lumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunization who have given birth to a child with a platelet count < 150 x 10 9/l in the first week of life;
2. HPA alloimmunization must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the fetus or homozygous partner;
3. The biological fathers are either homozygous positive for the HPA-type or heterozygous;
4. In the case of a heterozygous father the platelet antigen genotype of the fetus will be tested before 28 weeks by amniocentesis;
5. At inclusion, the pregnancy is an ultrasonographically proven intrauterine singleton pregnancy with a gestational age between 12 and 28 weeks;
6. All participating patients will give written informed consent after oral and written trial information.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Pregnant women with autoimmune thrombocytopenia;
2. Twins or multiple pregnancies;
3. Fetuses and neonates with major congenital anomalies or chromosomal abnormalities;
4. Women who have previously given birth to children with FNAIT with ICH. Women who have antibodies in the first pregnancy (discovered by chance, or for instance with a sister with FNAIT).
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL211 |
| NTR-old | NTR248 |
| Ander register | : N/A |
| ISRCTN | ISRCTN29462550 |